438 related articles for article (PubMed ID: 33906023)
1. Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives.
Larroquette M; Peyraud F; Domblides C; Lefort F; Bernhard JC; Ravaud A; Gross-Goupil M
Cancer Treat Rev; 2021 Jun; 97():102207. PubMed ID: 33906023
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Resch I; Enikeev D; Karakiewicz PI; Shariat SF; Schmidinger M
Urol Oncol; 2021 Nov; 39(11):764-773. PubMed ID: 34400065
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy in renal cell carcinoma.
Massari F; Di Nunno V; Ciccarese C; Graham J; Porta C; Comito F; Cubelli M; Iacovelli R; Heng DYC
Cancer Treat Rev; 2017 Nov; 60():152-157. PubMed ID: 28992528
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
6. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.
Ciccarese C; Strusi A; Arduini D; Russo P; Palermo G; Foschi N; Racioppi M; Tortora G; Iacovelli R
Cancer Treat Rev; 2023 Apr; 115():102528. PubMed ID: 36905896
[TBL] [Abstract][Full Text] [Related]
7. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
[TBL] [Abstract][Full Text] [Related]
8. The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.
Brown LC; Zhang T; George DJ
Cancer J; 2020; 26(5):376-381. PubMed ID: 32947305
[TBL] [Abstract][Full Text] [Related]
9. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
Catalano M; Procopio G; Sepe P; Santoni M; Sessa F; Villari D; Nesi G; Roviello G
Pharmacol Ther; 2023 Sep; 249():108499. PubMed ID: 37479037
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment in renal cell carcinoma.
Dizman N; Adashek JJ; Hsu J; Bergerot PG; Bergerot CD; Pal SK
Clin Adv Hematol Oncol; 2018 Aug; 16(8):555-563. PubMed ID: 30148828
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
Cosso F; Roviello G; Nesi G; Shabani S; Spatafora P; Villari D; Catalano M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835654
[TBL] [Abstract][Full Text] [Related]
13. Perioperative systemic therapy in renal cell carcinoma.
MacPhail C; Wood LA; Thana M
Curr Opin Support Palliat Care; 2023 Dec; 17(4):301-307. PubMed ID: 37800628
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology.
Tobert CM; Uzzo RG; Wood CG; Lane BR
Urol Oncol; 2013 Oct; 31(7):1316-20. PubMed ID: 22264501
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.
Fitzgerald KN; Motzer RJ; Lee CH
Nat Rev Urol; 2023 Mar; 20(3):179-193. PubMed ID: 36369389
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant and neoadjuvant therapy in renal cell carcinoma.
Choueiri M; Tannir N; Jonasch E
Curr Clin Pharmacol; 2011 Aug; 6(3):144-50. PubMed ID: 21827393
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
18. How Targeted Therapy Influence Renal Surgery for Renal Cell Carcinoma.
Greco F; Marchioni M; Esperto F; Papalia R; Schips L; Scarpa RM
Curr Drug Targets; 2020; 21(15):1550-1557. PubMed ID: 32621715
[TBL] [Abstract][Full Text] [Related]
19. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
Reed JP; Posadas EM; Figlin RA
Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
